Trial reportBritish journal of haematology2018
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Trial report in British journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.The oncologist · 2025Pooled it
- Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.Cancer chemotherapy and pharmacology · 2022Trial
- Review
- [Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.Saudi journal of biological sciences · 2024Review
- Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.Hematology reports · 2023Review
- 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.Haematologica · 2021Review
- Development of [European journal of nuclear medicine and molecular imaging · 2021Article
- What Is New in the Treatment of Smoldering Multiple Myeloma?Journal of clinical medicine · 2021Review
- Immunotherapy of Multiple Myeloma: Promise and Challenges.ImmunoTargets and therapy · 2021Review
- The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma.Pharmaceuticals (Basel, Switzerland) · 2020Review
- How we manage smoldering multiple myeloma.Hematology reports · 2020Article
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.Journal for immunotherapy of cancer · 2020Article
- High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.Best practice & research. Clinical haematology · 2020Review
- Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.Cancers · 2019Review
- Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies.Cancers · 2019Review
- A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.Blood advances · 2019Article
- Timing of treatment of smoldering myeloma: early treatment.Blood advances · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Smouldering multiple myeloma (SMM) is associated with increased risk of progression to multiple myeloma within 2 years, with no approved treatments. Elotuzumab has been shown to promote natural killer (NK) cell stimulation and antibody-dependent cellular cytotoxicity (ADCC) in vitro. CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.